AlphAIAlphAI — Financial news for AI agents
fool.comAUG 212 min read$LTRN

Lantern Pharma (LTRN) Q2 2026 Earnings Call Transcript

Lantern Pharma (LTRN) reported Q2 2026 earnings with $7.1M net loss, $7.4M cash, and reduced R&D expenses. LP-300 showed 8.9-month median PFS in L858R patients. The company is advancing LP-184 trials and plans to raise capital for Open Medicine AI, a new AI subsidiary. Management highlighted potential partnerships and cost efficiencies.

Original reporting
fool.com
Published Aug 21, 2026, 1:45 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 21, 2026, 2:26 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Lantern Pharma (LTRN) Q2 2026 Earnings Call Transcript — source image
Source · fool.com
Decision brief

The 30-second read

$LTRNNeutralMed
01

Why it matters

The earnings release offers fresh data on cash, loss, and expense trends, informing short‑term trading decisions.

02

Market read

First‑report earnings for a micro‑cap biotech; may trigger modest price movement.

03

What to watch

Potential dilution from future financing and execution risk of AI platform commercialization.

Relevance 7/10Novelty 7/10Timing: after market open

Background

Lantern Pharma (LTRN) held its Q2 2026 earnings call, providing detailed financial and clinical updates.

Company-level read

Ticker impact

$LTRNNeutralMedium confidence
Context

Q2 2026 earnings release showing net loss of $7.1M, cash $7.4M and a 42% YoY drop in R&D expense.

Expected impact

Potential modest upside if investors focus on loss reduction and cash raise plans.

Evidence & confidence

Earnings are better than prior year but the company remains loss-making and will need additional capital.

Market effects

Sector

Highlights cost‑efficiency trends in AI‑driven biotech sector.

Regional

Limited to US micro‑cap biotech investors.

Global

Shows emerging AI‑drug discovery model, but impact confined to niche investors.

Counterpoint

What could challenge this read

Loss reduction may be overstated; cash burn could accelerate with upcoming capital raises.

Key entities

  • Company
    Lantern Pharma Inc.

    Biotech firm developing AI‑enabled drug discovery platforms.

  • Executive
    Panna Sharma

    President and CEO of Lantern Pharma.

Read at source← All news

Related articles

OCT 8
$LTRNMedAI 8/10

Lantern Pharma secures Taiwan clearances for Phase II NSCLC study

Lantern Pharma has received regulatory and IRB approvals in Taiwan to begin Part 2 of its Phase II HARMONIC trial for LP-300 in advanced NSCLC patients. The trial will include up to eight cycles, increased from six, and aims to enroll patients with the EGFR exon 21 L858R mutation. The company expects further site approvals in Q4 and plans to leverage regional data for potential partnerships. According to the CEO, the trial focuses on a high-need area in East Asia.

finance.yahoo.com2 min
OCT 7
$LTRNMedAI 8/10

Lantern Pharma Receives Taiwan Approvals to Open Next Stage of P

Lantern Pharma (LTRN) received Taiwan approvals to advance its Phase 2 HARMONIC™ trial of LP-300. The trial now allows up to eight cycles of treatment, supported by preliminary data showing longer progression-free survival. Taiwan's high lung cancer prevalence and EGFR mutation rates may aid enrollment. The company is exploring regional partnerships for LP-300.

gurufocus.com2 min
AUG 14
$LTRNMed

Lantern Pharma Reports Second Quarter 2026 Financial Results and Provides Business Update

Lantern Pharma Inc. (LTRN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Lantern Pharma Reports Second Quarter 2026 Financial Results and Provides Business Update Open Medicine AI Established as a Separate Company with Executed Commercial Licenses; Progression-Free Survival Benefit Deepens in EGFR Exon 21 L858R Lung Cancer with LP-300; EM

SEC EDGAR 8-K6 min
JUL 23
$LTRNMed

Lantern Pharma Receives U.S. Patent Allowance for LP

Lantern Pharma (NASDAQ: LTRN) said the U.S. Patent and Trademark Office issued a Notice of Allowance for a patent covering patient selection and treatment for ovarian, primary liver, kidney and thyroid cancers using LP-184 (zirdafulven). The allowed claims relate to a three-gene biomarker signature (PTGR1, PTPN14, ASPH). Lantern cited a 45% disease control rate at or above the effective dose in Phase 1a and plans multiple Phase 1b/2 studies in 2026.

citybuzz.co3 min